.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,126,920

« Back to Dashboard
Patent 6,126,920 protects LUXIQ and OLUX and is included in two NDAs. There have been zero Paragraph IV challenges on Luxiq and Olux There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has twenty-six patent family members in twenty countries.

Summary for Patent: 6,126,920

Title: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Abstract:Methods of treating various skin diseases, and in particular, scalp psoriasis, utilizing a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent are disclosed. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
Inventor(s): Jones; Julie Irene (Herpenden, GB), Baker; Anthony Richard (West Horsley, GB), Halls; Neil Graham (Glen Waverley, AU), Watmough; Peter (Grimsby, GB), Marriott; Peter (Grimsby, GB)
Assignee: Medeva Europe PLC (London, GB)
Application Number:08/913,144
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 4th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Delcor Asset Corp
LUXIQ
betamethasone valerate
AEROSOL, FOAM;TOPICAL020934-001Feb 28, 1999RXYes6,126,920► subscribe METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
Delcor Asset Corp
OLUX
clobetasol propionate
AEROSOL, FOAM;TOPICAL021142-001May 26, 2000RXYes6,126,920► subscribe METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,126,920

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9504265Mar 03, 1995
PCT Information
PCT FiledMarch 01, 1996PCT Application Number:PCT/GB96/00490
PCT Publication Date:September 12, 1996PCT Publication Number: WO96/27376

Non-Orange Book Patents for Patent: 6,126,920

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,078,058Corticosteroid-containing pharmaceutical composition► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,126,920

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria253367► subscribe
Australia4885196► subscribe
Australia709320► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc